Drug Profile
Research programme: macrocyclic peptide therapeutics - Daiichi Sankyo/PeptiDream
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; PeptiDream
- Developer PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Japan